Clinical Trials Browser

Phase 2 × Lymphoma, Extranodal NK-T-Cell × 90 days × Clear all

NCT07457177 2026-03-09

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Phase 2 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

NCT07385989 2026-02-04

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell